ArriVent BioPharma, Inc. (AVBP) vs Damora Therapeutics, Inc. (DMRA)
A side-by-side comparison of ArriVent BioPharma, Inc. and Damora Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$28.46HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
DMRA
Damora Therapeutics, Inc.
$20.22HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — AVBP vs DMRA
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)DMRA +20.7% (+6.5%/yr)AVBP compounded faster over this window
AVBP DMRA
AVBP vs DMRA: by the numbers
- •AVBP is the larger company ($1.33B vs $1.24B market cap).
Metrics side by side
Valuation
| Metric | AVBP | DMRA |
|---|---|---|
| P/B ratio | 3.61 | 3.22 |
Profitability
| Metric | AVBP | DMRA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -44.63% | -50.93% |
| ROIC | -47.96% | -52.44% |
Growth (annualized)
| Metric | AVBP | DMRA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -25.05% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.